Germany
· Delayed Price · Currency is EUR Cosmo Pharmaceuticals Statistics
Total Valuation
Cosmo Pharmaceuticals has a market cap or net worth of EUR 1.03 billion. The enterprise value is 899.39 million.
| Market Cap | 1.03B |
| Enterprise Value | 899.39M |
Important Dates
The next estimated earnings date is Friday, February 14, 2025.
| Earnings Date | Feb 14, 2025 |
| Ex-Dividend Date | Jul 10, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.77% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 8.42M |
Valuation Ratios
The trailing PE ratio is 14.79.
| PE Ratio | 14.79 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 10.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.65, with an EV/FCF ratio of 7.89.
| EV / Earnings | 12.93 |
| EV / Sales | 4.69 |
| EV / EBITDA | 8.65 |
| EV / EBIT | 10.12 |
| EV / FCF | 7.89 |
Financial Position
The company has a current ratio of 4.85, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.85 |
| Quick Ratio | 4.35 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | 21.40 |
Financial Efficiency
Return on equity (ROE) is 14.80% and return on invested capital (ROIC) is 9.59%.
| Return on Equity (ROE) | 14.80% |
| Return on Assets (ROA) | 7.82% |
| Return on Capital (ROIC) | 9.59% |
| Revenue Per Employee | 546,773 |
| Profits Per Employee | 205,230 |
| Employee Count | 325 |
| Asset Turnover | 0.27 |
| Inventory Turnover | 3.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +13.89% |
| 50-Day Moving Average | 68.60 |
| 200-Day Moving Average | 73.06 |
| Relative Strength Index (RSI) | 35.11 |
| Average Volume (20 Days) | 130 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cosmo Pharmaceuticals had revenue of EUR 185.36 million and earned 69.57 million in profits. Earnings per share was 4.32.
| Revenue | 185.36M |
| Gross Profit | 141.74M |
| Operating Income | 85.98M |
| Pretax Income | 86.61M |
| Net Income | 69.57M |
| EBITDA | 99.91M |
| EBIT | 85.98M |
| Earnings Per Share (EPS) | 4.32 |
Balance Sheet
The company has 133.41 million in cash and 1.46 million in debt, giving a net cash position of 131.96 million.
| Cash & Cash Equivalents | 133.41M |
| Total Debt | 1.46M |
| Net Cash | 131.96M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 505.39M |
| Book Value Per Share | 31.06 |
| Working Capital | 145.72M |
Cash Flow
In the last 12 months, operating cash flow was 117.33 million and capital expenditures -3.34 million, giving a free cash flow of 113.99 million.
| Operating Cash Flow | 117.33M |
| Capital Expenditures | -3.34M |
| Free Cash Flow | 113.99M |
| FCF Per Share | n/a |
Margins
Gross margin is 76.47%, with operating and profit margins of 46.38% and 37.53%.
| Gross Margin | 76.47% |
| Operating Margin | 46.38% |
| Pretax Margin | 46.72% |
| Profit Margin | 37.53% |
| EBITDA Margin | 53.90% |
| EBIT Margin | 46.38% |
| FCF Margin | 61.50% |
Dividends & Yields
Cosmo Pharmaceuticals does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 6.07% |
| Buyback Yield | 0.77% |
| Shareholder Yield | 0.77% |
| Earnings Yield | 7.02% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cosmo Pharmaceuticals has an Altman Z-Score of 5.97.
| Altman Z-Score | 5.97 |
| Piotroski F-Score | n/a |